Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Testicular cancer from diagnosis to epigenetic factors.
Boccellino M, Vanacore D, Zappavigna S, Cavaliere C, Rossetti S, D'Aniello C, Chieffi P, Amler E, Buonerba C, Di Lorenzo G, Di Franco R, Izzo A, Piscitelli R, Iovane G, Muto P, Botti G, Perdonà S, Caraglia M, Facchini G. Boccellino M, et al. Among authors: cavaliere c. Oncotarget. 2017 Sep 18;8(61):104654-104663. doi: 10.18632/oncotarget.20992. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262668 Free PMC article. Review.
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: cavaliere c. Cancer Chemother Pharmacol. 2011 Jun;67(6):1455-61. doi: 10.1007/s00280-011-1594-z. Epub 2011 Mar 2. Cancer Chemother Pharmacol. 2011. PMID: 21365219 Clinical Trial.
Peg-filgrastim and cabazitaxel in prostate cancer patients.
Di Lorenzo G, DʼAniello C, Buonerba C, Federico P, Rescigno P, Puglia L, Ferro M, Bosso D, Cavaliere C, Palmieri G, Sonpavde G, De Placido S. Di Lorenzo G, et al. Among authors: cavaliere c. Anticancer Drugs. 2013 Jan;24(1):84-9. doi: 10.1097/CAD.0b013e32835a56bc. Anticancer Drugs. 2013. PMID: 23044721
Intravesical chemo-immunotherapy in non muscle invasive bladder cancer.
Leopardo D, Cecere SC, Di Napoli M, Cavaliere C, Pisano C, Striano S, Marra L, Menna L, Claudio L, Perdonà S, Setola S, Berretta M, Franco R, Tambaro R, Pignata S, Facchini G. Leopardo D, et al. Among authors: cavaliere c. Eur Rev Med Pharmacol Sci. 2013 Aug;17(16):2145-58. Eur Rev Med Pharmacol Sci. 2013. PMID: 23893180 Free article. Review.
Endocrine disruptors and female cancer: Informing the patients (Review).
Del Pup L, Mantovani A, Luce A, Cavaliere C, Facchini G, Di Francia R, Caraglia M, Berretta M. Del Pup L, et al. Among authors: cavaliere c. Oncol Rep. 2015 Jul;34(1):3-11. doi: 10.3892/or.2015.3997. Epub 2015 May 20. Oncol Rep. 2015. PMID: 25998096 Review.
Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen.
Perri F, Pisconti S, Conson M, Pacelli R, Della Vittoria Scarpati G, Gnoni A, D'Aniello C, Cavaliere C, Licchetta A, Cella L, Giuliano M, Schiavone C, Falivene S, Di Lorenzo G, Buonerba C, Ravo V, Muto P. Perri F, et al. Among authors: cavaliere c. Onco Targets Ther. 2015 Jun 8;8:1345-9. doi: 10.2147/OTT.S75232. eCollection 2015. Onco Targets Ther. 2015. PMID: 26089683 Free PMC article.
497 results